Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis

[1]  K. Yoneyama,et al.  Late gadolinium enhancement on cardiac magnetic resonance images predicts reverse remodeling in patients with nonischemic cardiomyopathy treated with carvedilol. , 2013, International journal of cardiology.

[2]  A. Kadish,et al.  Significance of follow-up left ventricular ejection fraction measurements in the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation trial (DEFINITE). , 2013, Heart rhythm.

[3]  Thomas C. Crawford,et al.  Implantable Cardioverter Defibrillator Therapy in Patients with Cardiac Sarcoidosis , 2012, Journal of cardiovascular electrophysiology.

[4]  F. Marchlinski,et al.  Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. , 2012, Heart rhythm.

[5]  Jon Hainer,et al.  Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. , 2012, Journal of the American College of Cardiology.

[6]  E. Leung,et al.  Arrhythmias in cardiac sarcoidosis: diagnosis and treatment , 2012, Current opinion in cardiology.

[7]  R. Boellaard.  Need for Standardization of 18F-FDG PET/CT for Treatment Response Assessments , 2011, The Journal of Nuclear Medicine.

[8]  G. Youssef,et al.  Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment , 2011, Heart.

[9]  H. Ohira,et al.  18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  Michael C Iannuzzi,et al.  Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. , 2011, JAMA.

[11]  R. Boellaard.  Standards for PET Image Acquisition and Quantitative Data Analysis , 2009, Journal of Nuclear Medicine.

[12]  Uchechukwu Sampson,et al.  Value of vasodilator left ventricular ejection fraction reserve in evaluating the magnitude of myocardium at risk and the extent of angiographic coronary artery disease: a 82Rb PET/CT study. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  J. Grutters,et al.  Corticosteroid treatment in sarcoidosis , 2006, European Respiratory Journal.

[14]  T. Yokoyama,et al.  Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  M. Isobe,et al.  Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. , 2001, The American journal of cardiology.

[16]  R. Baughman,et al.  Prolonged use of methotrexate for sarcoidosis. , 1995, Archives of internal medicine.

[17]  G. Hutchins,et al.  Cardiac Sarcoid: A Clinicopathologic Study of 84 Unselected Patients with Systemic Sarcoidosis , 1978, Circulation.

[18]  S. Nakatani,et al.  Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. , 2005, The American journal of cardiology.